VIDEO: Abiraterone promising for prostate cancer in two trials
In this video, Eugene Shenderov, MD, PhD, discusses the STAMPEDE and PEACE-1 studies, which evaluated the addition of abiraterone acetate plus prednisolone to standard therapy for patients with prostate cancer.
"We have more efficacious therapy earlier on by adding abiraterone," Shenderov, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, said.
As the research moves agents such as abiraterone earlier into earlier settings and into combination therapy, it may affect therapeutic options further down the line, which means fewer options may be available, he said.
Collapse
Fizazi, K et al. Abstract LBA5_PR. Presented at ESMO Congress 2021 (virtual meeting); Sept. 16-21, 2021.
Attard G, et al. Abstract LBA4_PR. Presented at ESMO Congress 2021 (virtual meeting); Sept. 16-21, 2021.
Read more about